Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Lee, Jeeyun ^a   Sohn, Insuk ^b   Do, In Gu ^a,b   Kim, Kyoung Mee ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Sohn, Tae Sung ^a   Bae, Jae Moon ^a   Choi, Min Gew ^a   Lim, Do Hoon ^a   Min, Byung Hoon ^a   Lee, Joon Haeng ^a   Rhee, Poong Lyul ^a   Kim, Jae J ^a   Choi, Dong Il ^a   Tan, Iain Beehuat ^c   Das, Kakoli ^d   Tan, Patrick ^c,d,e   Jung, Sin Ho ^b   Kang, Won Ki ^a   Kim, Sung ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CDC25B GENE; CDK1 GENE; CLIP4 GENE; COHORT ANALYSIS; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LAMP5 GENE; LTB4R2 GENE; MAJOR CLINICAL STUDY; MATN3 GENE; MICROARRAY ANALYSIS; NOX4 GENE; RISK ASSESSMENT; STOMACH CANCER; TFDP1 GENE; TISSUE SECTION; VALIDATION PROCESS; ADENOCARCINOMA; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; STOMACH NEOPLASMS;

CARRIER PROTEIN; CLIP4 PROTEIN, HUMAN; LAMP5 PROTEIN, HUMAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MATN3 PROTEIN, HUMAN; MATRILIN; NOX4 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTOME; TUMOR MARKER;

ADENOCARCINOMA; CARRIER PROTEINS; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MATRILIN PROTEINS; NADPH OXIDASE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; STOMACH NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897139887     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090133     Document Type: Article

References (21)

1. Levi F, Lucchini F, Gonzalez JR, Fernandez E, Negri E, et al. (2004) Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 15: 338-345. (Pubitemid 38262637)
2. Folli S, Morgagni P, Roviello F, De Manzoni G, Marrelli D, et al. (2001) Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 31: 495-499. (Pubitemid 33039764)
3. Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, et al. (1999) Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 230: 433-438; discussion 438-440.
4. Bang YJ, Kim YW, Yang H, Chung HC, Park YK, et al. (2011) Adjuvant capecitabine and oxaliplatin for gastric cancer: results of the Phase III CLASSIC trial. J of Clin Oncol 29 (Abstr LBA 4002).
5. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379: 315-321.
6. Lee J, Lim do H, Kim S, Park SH, Park JO, et al. (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30: 268-273.
7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730.
8. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, et al. (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63: 1279-1285. (Pubitemid 41628018)
9. Lee K, Kye M, Jang JS, Lee OJ, Kim T, et al. (2004) Proteomic analysis revealed a strong association of a high level of alpha1-antitrypsin in gastric juice with gastric cancer. Proteomics 4: 3343-3352. (Pubitemid 39525282)
10. Sohn I, Kim J, Jung SH, Park C (2009) Gradient lasso for Cox proportional hazards model. Bioinformatics 25: 1775-1781.
11. Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, et al. (2004) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165: 1799-1807. (Pubitemid 39435177)
12. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26: 317-325. (Pubitemid 351355126)
13. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
14. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, et al. (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14: 878-885. (Pubitemid 38660505)
15. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, et al. (2011) Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141: 476-485, 485 e471-411.
16. Simon R, Radmacher MD, Dobbin K, McShane LM (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18. (Pubitemid 36124291)
17. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, et al. (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21: 241-250. (Pubitemid 46606152)
18. Clark-Langone KM, Wu JY, Sangli C, Chen A, Snable JL, et al. (2007) Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 8: 279.
19. Yasui K, Okamoto H, Arii S, Inazawa J (2003) Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. J Hum Genet 48: 609-613. (Pubitemid 38031301)
20. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, et al. (2002) TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35: 1476-1484. (Pubitemid 34966902)
21. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, et al. (2011) Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17: 1850-1857.